Aniban, Rhofe P.
HRN: 21-28-10 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/22/2022
CEFTAZIDIME 1GM (VIAL)
04/22/2022
04/29/2022
IV
1gram
Q8hrs
Parapneumonic Process
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes